IL289881A - Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide - Google Patents

Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide

Info

Publication number
IL289881A
IL289881A IL289881A IL28988122A IL289881A IL 289881 A IL289881 A IL 289881A IL 289881 A IL289881 A IL 289881A IL 28988122 A IL28988122 A IL 28988122A IL 289881 A IL289881 A IL 289881A
Authority
IL
Israel
Prior art keywords
inden
oxadiazol
polymorphs
tetrazole
carboxamide
Prior art date
Application number
IL289881A
Other languages
English (en)
Hebrew (he)
Inventor
TOM Norma
Andersen Denise
Original Assignee
Cytokinetics Inc
TOM Norma
Andersen Denise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, TOM Norma, Andersen Denise filed Critical Cytokinetics Inc
Publication of IL289881A publication Critical patent/IL289881A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL289881A 2019-07-17 2022-01-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide IL289881A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17
PCT/US2020/042390 WO2021011809A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Publications (1)

Publication Number Publication Date
IL289881A true IL289881A (en) 2022-03-01

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289881A IL289881A (en) 2019-07-17 2022-01-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide

Country Status (16)

Country Link
US (1) US20220274969A1 (https=)
EP (1) EP3999181B1 (https=)
JP (1) JP2022542803A (https=)
KR (1) KR20220082803A (https=)
CN (1) CN114667283B (https=)
AU (1) AU2020315433A1 (https=)
BR (1) BR112022000523A2 (https=)
CA (1) CA3144974A1 (https=)
CL (1) CL2022000089A1 (https=)
ES (1) ES2982707T3 (https=)
IL (1) IL289881A (https=)
MX (1) MX2022000498A (https=)
NZ (1) NZ784931A (https=)
PH (1) PH12022550084A1 (https=)
TW (1) TW202116764A (https=)
WO (1) WO2021011809A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
US20220274969A1 (en) 2022-09-01
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
AU2020315433A1 (en) 2022-03-03
JP2022542803A (ja) 2022-10-07
NZ784931A (en) 2025-03-28
PH12022550084A1 (en) 2023-04-12
ES2982707T3 (es) 2024-10-17
CA3144974A1 (en) 2021-01-21
EP3999181A1 (en) 2022-05-25
TW202116764A (zh) 2021-05-01
MX2022000498A (es) 2022-02-03
EP3999181C0 (en) 2024-05-29
WO2021011809A1 (en) 2021-01-21
BR112022000523A2 (pt) 2022-03-03
CL2022000089A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
IL289875A (en) 3. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl- 1h-pyrazole-4-carboxamide
IL289881A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
PH12020551304A1 (en) Novel crystalline forms
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
SG11202001868RA (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
MX2017014846A (es) Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol.
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
HK40075684B (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
IL288577A (en) Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
HK40131421A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
SI3643704T1 (sl) Novi intermediati za pripravo remifentanil hidroklorida
PH12017500123A1 (en) Crystal of azole benzene derivative
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
IL289891A (en) Solid formulations of a 1,2,3-oxadiazole derivative
HK40081030A (en) Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
MY180730A (en) Azole benzene derivative and crystalline form thereof
HK40072159A (en) Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
HK40064245A (en) Use of 8,9-dihydrocannabidiol compounds
PH12018500898A1 (en) Inhibitor of the p2x7 receptor
TH91426B (th) ตู้เย็น